Results 201 to 210 of about 53,113 (297)

The Potential of Phytochemicals to Overcome Multidrug Resistance in Metastatic Melanoma

Chemistry &Biodiversity, Volume 23, Issue 1, January 2026.
ABSTRACT Metastatic melanoma is the most lethal form of skin cancer, accounting for most skin cancer‐related deaths. Immunotherapies and targeted therapies have improved overall and progression‐free survival rates in metastatic melanoma patients. The effectiveness of these therapies decreases due to multidrug resistance (MDR).
Jacqueline Maphutha, Danielle Twilley, Mona Dawood, Thomas Efferth, Namrita Lall   +4 more
wiley   +1 more source

Neoadjuvant nab-paclitaxel in the treatment of breast cancer [PDF]

, 2016
Eleftherios P. Mamounas, Naoto T. Ueno
core   +1 more source

Supplementary Table S1 from Phase I Study of SYNB1891, an Engineered <i>E. coli</i> Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Jason J. Luke, Sarina A. Piha‐Paul, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Jankú   +10 more
openalex   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source

Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report. [PDF]

Discov Oncol
Liu J, Zhao Z, Tian Y, Shao H.
europepmc   +1 more source

OP02-3 Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study [PDF]

Jin Sung Kim, Byung Moon Kang, Chansik An, Yijun Kang, I. Kim, Hyunjin Kim, Chong Kim, Hongjae Chon   +7 more
openalex   +1 more source

Immune Checkpoint Inhibitor‐Associated Myocarditis With Myositis/Myasthenia Gravis Overlap Syndrome: Two Case Reports Highlighting Early Onset, Diagnostic Uncertainty, and Management Considerations

Clinical Case Reports, Volume 14, Issue 1, January 2026.
Custom illustration created by the author in collaboration with the Mayo Clinic Digital Media Department. ABSTRACT Immune checkpoint‐inhibitors (ICIs) have revolutionized and significantly improved cancer care through remarkable efficacy, but significant adverse effects have been observed.
Artur Schneider, Nikita Jhawar, Deepica Reddy, Razvan Chirila   +3 more
wiley   +1 more source

Clinical Course and Risk Factors of Lenvatinib‐Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Lenvatinib‐related hypothyroidism occurs in 16%–22% of patients with hepatocellular carcinoma and may affect treatment management. Previous studies have reported elevated serum thyroid stimulating hormone (TSH) levels despite levothyroxine therapy, indicating the need for research on the optimal levothyroxine dose during lenvatinib ...
Chihiro Shiraishi, Hideo Kato, Yuki Asai, Takuya Iwamoto   +3 more
wiley   +1 more source

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) [PDF]

, 2018
et al,, Picus, Joel
core   +1 more source

Gyógyítható lesz-e a melanoma? Perspektívák a melanoma kezelésében = Will melanoma be curable? Perspectives in melanoma therapy [PDF]

, 2017
Baltás, Eszter, Gyulai, Rolland, Lengyel, Zsuzsanna   +2 more
core   +1 more source